- Home
- GSHD vs SUPN Comparison
GSHD vs SUPN Comparison
Compare GSHD & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | SUPN |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GSHD | SUPN |
|---|---|---|
| Price | $50.07 | $41.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | ★ $62.08 | $60.50 |
| AVG Volume (30 Days) | 407.9K | ★ 723.4K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | $365,304,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $16.52 | $22.95 |
| Revenue Next Year | $15.57 | $54.39 |
| P/E Ratio | $43.72 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $33.68 | $37.54 |
| 52 Week High | $79.85 | $59.68 |
Technical Indicators
Market Signals| Indicator | GSHD | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 45.74 |
| Support Level | $49.11 | $40.51 |
| Resistance Level | $56.00 | $52.30 |
| Average True Range (ATR) | 2.30 | 1.72 |
| MACD | 1.13 | -0.03 |
| Stochastic Oscillator | 97.71 | 60.87 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.